Tumor patients with high Rad51 expression tend to experience poor radiotherapy response, whereas pharmacological inhibition of Rad51 dramatically increases radiosensitivity in prostate, breast, and lung cancers [30, 31]. This evidence concerns the gene RAD51 and lung cancer.